Clinical Trials Directory

Trials / Terminated

TerminatedNCT02134717

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Kevin F. Gibson · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis. Subjects with active sarcoidosis will first undergo bronchoscopy with bronchoalveolar lavage to recover lung immune cells for baseline analysis. They will then receive the drug maraviroc for 6 weeks duration. They will then undergo a repeat bronchoscopy with bronchoalveolar lavage to recover lung immune cells for analysis following maraviroc treatment.

Detailed description

The investigators hypothesize that inhibition of CCR5 by maraviroc may have a beneficial immunomodulatory effect on the granulomatous inflammation of pulmonary sarcoidosis. The specific aim of this proposal is the investigate the effect of CCR5 inhibition on the trafficking of mononuclear cells to the lung, skin, peripheral blood in subjects with active sarcoidosis exposed to the CCR5 inhibitor, maraviroc. A second aim will be to isolate by cell sorting cluster of differentiation 4 (CD4)+CCR5+ T cells for amplified gene expression profiling before and after CCR5 inhibition, experiments the investigators believe will elucidate genes associated with downstream activation and inhibition of CCR5 receptor function.

Conditions

Interventions

TypeNameDescription
DRUGall subjects will receive maraviroc 300mg orally twice a day for 6 weeks
PROCEDUREBronchoscopy with bronchoalveolar lavageBronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
PROCEDUREvenipuncturesVenipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
PROCEDURESkin biopsyFor subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.

Timeline

Start date
2014-01-01
Primary completion
2015-05-01
Completion
2015-05-01
First posted
2014-05-09
Last updated
2025-12-03
Results posted
2017-07-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02134717. Inclusion in this directory is not an endorsement.

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes (NCT02134717) · Clinical Trials Directory